A review of inhaled loxapine emphasizes administration requirements that matter when comparing agitation treatments.
A different treatment pathway
The review describes rapid absorption and clinical-development evidence for agitation associated with schizophrenia or bipolar mania. It discusses lorazepam among comparator treatments while noting that inhaled treatment requires some patient cooperation and carries respiratory concerns.
Comparability depends on who can receive it
A patient able to use an inhalation device may differ from someone requiring an injection during severe agitation. A review’s broad comparison is not proof that all regimens are equally effective for the same patients. The supplied paper’s historical regulatory discussion also should not be relabeled as current requirements without a separate current-law question. Its useful contribution is showing that acceptability, route, cooperation and respiratory status are part of treatment selection. Speed or a favorable efficacy description alone does not settle the choice in an individual episode.
Source paper
Original analysis of the supplied journal article, identified as PMC6689540.
Leave a Reply